ValuEngine Downgrades Medifast (MED) to Hold


MED has been the topic of several other research reports. Zacks Investment Research raised shares of Medifast from a "hold" rating to a "buy" rating and set a $79.00 target price on the stock in a report on Friday, November 10th.



from Biotech News